ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 13.6% during mid-day trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.09 ($0.05). Approximately 21,797,100 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 19,107,500 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The stock’s 50-day simple moving average is GBX 1.71 and its two-hundred day simple moving average is GBX 1.72. The stock has a market cap of £16.65 million, a price-to-earnings ratio of -399.90 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Do S&P 500 Stocks Tell Investors About the Market?
- Abbott Laboratories Will Outperform Healthcare Stocks in 2025
- Upcoming IPO Stock Lockup Period, Explained
- PepsiCo: 53 Years of Dividend Growth and Still Going Strong
- Find and Profitably Trade Stocks at 52-Week Lows
- Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
